CERE-120: Adeno-Associated Virus Delivery of Neurturin ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00985517 (ClinicalTrials.gov) | October 29, 2009 | 25/9/2009 | Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease | A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease | Idiopathic Parkinson's Disease | Biological: CERE-120: Adeno-Associated Virus Delivery of Neurturin;Procedure: Sham Surgery | Sangamo Therapeutics | NULL | Completed | 35 Years | 70 Years | All | 57 | Phase 1/Phase 2 | United States |